Urinary Incontinence (UI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

London, United Kingdom (PressExposure) November 10, 2011 -- GlobalData estimated the global Urinary Incontinence (UI) therapeutics market to be worth $2.6 billion in 2010. It is expected to grow to $4.5 billion, with a Compound Annual Growth Rate (CAGR) of 7.0% by 2018. The modest growth is primarily attributable to the patent expiries of key drugs in the market such as Detrol (tolterodine) and VESIcare(solifenacin). However, the increase in the diseased population and the recent approval of premium priced products such as Botox are expected to sustain the UI therapeutics market. The market remains well-served with the current marketed products, most of which are moderately efficacious in their respective target areas but weak safety profiles are a concern.

The UI therapeutics market is currently made up of drugs which possess moderate efficacy profiles, however,an unmet need exists,which is attributable to the inability of these drugs to offer absolute patient compliance, patient satisfaction and drug safety. The non-compliance of the currently marketed drugs is due to their limited efficacy and bothersome adverse effects. Also, the currently available drugs possess similar mechanisms of action, thus, opening the UI therapeutics market to new entrants offering better safety, efficacy and novel mechanisms of action.

The UI therapeutics developmental pipeline has 44 molecules in various phases of clinical and preclinical development. The pipeline assessment defines molecules as first-in-class, me-too, and product extensions. Within the pipeline there are only six molecules in late-stage (Pre-registration and Phase III) development, and whilst there are 16 first-in-class molecules the majority of them are in early phases of development and are not expected to impact the UI therapeutics market during the forecast period (2011- 2018). The majority of these first-in-class molecules are transient receptor potential vanilloid (TRPV) antagonists and beta 3 adrenergic receptor antagonists. These molecules are expected to demonstrate superior safety and efficacy profiles as compared to the existing marketed products. There are 13 product extensions in the current pipeline which primarily focus on improved safety profile with longer and target specific action.

For Sample Pages, please click or add the below link to your browser:


GlobalData, the industry analysis specialist, has released its new report, "Urinary Incontinence (UI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global UI therapeutics market and identifies the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global UI therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

For further details, please click or add the below link to your browser:


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:

North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

About GlobalData

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

Press Release Source: http://PressExposure.com/PR/GlobalData.html

Press Release Submitted On: November 10, 2011 at 4:00 am
This article has been viewed 25397 time(s).